FTSE 100 today: UK stocks open lower, pound at $1.33; oil tops $100 amid conflict

Brent crude traded at $104.31 (08:41 GMT) amid Middle East tensions, sending the FTSE 100 down 1.6%, DAX -2.3%, CAC 40 -2.6% and GBP/USD to 1.3306 (-0.8%). Jefferies highlights market pricing of >1.5 ECB hikes and <1 BoE cut for 2026 but expects no ECB action this year unless oil stays above $100 and triggers second‑round effects; it also says if oil falls below $80 within three months ECB policy likely unaffected. Corporate moves: M&C Saatchi CEO Zaid Al‑Qassab will step down and leave the board on March 31, 2026 with Dame Heather Rabbatts as interim Executive Chair, and GSK licensed worldwide rights to linerixibat to Alfasigma.

Analysis

A near-term energy shock is amplifying position-driven volatility in rates and FX rather than a clear shift in underlying inflation expectations. Markets have historically overshot on front-end rate repricing within days-to-weeks when commodity risk jumps, then mean-revert if the shock proves transitory; only persistent pass-through into wages and services (a multi-quarter process) forces durable central bank action.

Winners are asymmetric: upstream producers and owners of fixed-price production convert spot moves into immediate incremental cash flow, while fuel-intensive sectors — airlines, container shipping, and inland logistics — experience margin pressure with a 2–3 quarter lag as higher freight and insurance feed through contracts. Currency and sovereign spread divergences will widen: commodity-exporting balance sheets and bank books improve, whereas import-dependent economies see near-term real-rate tightening via FX weakness even without policy moves.

For large diversified pharma, shedding late-stage or niche development obligations reduces capex and clinical spend volatility, improving optionality for buybacks/dividends but truncating upside if a drug becomes a breakout seller; the net valuation effect is typically modest and realized over 6–12 months. Management credibility on returning freed cash to shareholders versus reinvesting in higher-risk pipeline programs is the key behavioural catalyst that will move the stock multiple.

The consensus is overstating the immediacy of policy tightening risk from this episode: unless energy-driven core inflation shows serial pass-through into services over two consecutive NFP/PMI prints, expect markets to retrace a large part of front-end repricing. That makes tactical directional plays on energy and selective defensives compelling for a months-long horizon, but they should be paired with disciplined event stops tied to inflation prints and shipping/freight indicators.

Key Decisions for Investors

• Long XOM or CVX call spread (6–9 month tenor): buy a 1–2x call spread to capture asymmetric upside if commodity prices remain elevated while capping premium paid. Target 40–60% upside on option premium if E&P FCF re-rates; stop-loss at 60% premium loss.
• Short IAG (or UAL) via puts (3-month horizon): buy downside protection (puts) or short-stock exposure to airlines to capture margin compression ahead of quarterly guidance revisions. Expect 10–25% downside if jet-fuel passthrough and freight costs remain elevated; position size capped to 2–3% portfolio risk.
• Pair trade: long XLE / short XLI (3–6 months): exploit sector divergence as energy producers capture commodity windfall while industrials face input-cost pressure and order deferrals. Target spread tightening equivalent to 400–600bps sector-relative performance; implement with equal notional sizes and 5% stop on absolute loss.
• Long GSK (6–12 months) on modest size (ticker: GSK): buy into any headline-driven weakness with a time arbitrage on cash-flow de-risking and potential capital return optionality. Aim for 15–25% total return to target; hedge with a 25–30% out-of-the-money put if near-term macro volatility spikes.